LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

Search

REVOLUTION Medicines Inc

Затворен

СекторЗдравеопазване

39.73 2.63

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

39.48

Максимум

39.85

Ключови измерители

By Trading Economics

Приходи

-19M

-213M

EPS

-1.13

Марж на печалбата

-74.379

Служители

616

EBITDA

-24M

-237M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+76.24% upside

Дивиденти

By Dow Jones

Следващи печалби

6.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-147M

7.4B

Предишно отваряне

37.1

Предишно затваряне

39.73

Настроения в новините

By Acuity

50%

50%

153 / 381 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

REVOLUTION Medicines Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.05.2025 г., 20:33 ч. UTC

Придобивния, сливания и поглъщания

Salesforce in Talks to Buy Informatica, Bloomberg Reports, Citing Sources

24.05.2025 г., 08:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

24.05.2025 г., 08:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

24.05.2025 г., 07:00 ч. UTC

Печалби

Retailers Are Giving Mixed Messages on Prices. What Will s Really Happen at Checkout. -- Barrons.com

23.05.2025 г., 21:57 ч. UTC

Горещи акции

Stocks to Watch: Apple, Booz Allen, Constellation Energy, Intuit -- WSJ

23.05.2025 г., 21:15 ч. UTC

Топ новини

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23.05.2025 г., 21:04 ч. UTC

Придобивния, сливания и поглъщания

Real-Estate Broker Douglas Elliman Could See Takeover Battle After Report of Bid -- Barrons.com

23.05.2025 г., 20:56 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

Salesforce Back in Deal Talks With Informatica -- WSJ

23.05.2025 г., 20:51 ч. UTC

Топ новини

Boeing in Tentative Agreement to Pay $1.1 Billion to Avoid Trial for 737 MAX Crashes -- WSJ

23.05.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

23.05.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

23.05.2025 г., 20:41 ч. UTC

Топ новини

Stocks Fall on Tariff Broadside, After Week of Bond Market Agita -- WSJ

23.05.2025 г., 20:28 ч. UTC

Топ новини

Trump Threatens EU With 50% Tariffs, Takes Aim at Apple; Nasdaq Drops -- WSJ

23.05.2025 г., 20:06 ч. UTC

Топ новини

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 5th Update

23.05.2025 г., 20:06 ч. UTC

Придобивния, сливания и поглъщания

Salesforce Stock Drops, Informatica Soars. A Deal May Be Back on the Table. -- Barrons.com

23.05.2025 г., 19:50 ч. UTC

Топ новини

Trump's Tariffs: Where Things Stand -- 16th Update

23.05.2025 г., 19:28 ч. UTC

Придобивния, сливания и поглъщания

Trump on Truth Social: 'Bulk of That Investment Will Occur in the Next 14 Months'

23.05.2025 г., 19:28 ч. UTC

Придобивния, сливания и поглъщания

Trump on Truth Social: 'This Will Be a Planned Partnership Between United States Steel and Nippon Steel'

23.05.2025 г., 19:27 ч. UTC

Придобивния, сливания и поглъщания

Trump on Truth Social: 'Proud to Announce That, After Much Consideration and Negotiation, US Steel Will REMAIN in America'

23.05.2025 г., 19:20 ч. UTC

Пазарно говорене

Crude Futures Post Modest Weekly Losses -- Market Talk

23.05.2025 г., 19:18 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures End Week Unchanged -- Market Talk

23.05.2025 г., 18:57 ч. UTC

Топ новини

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23.05.2025 г., 18:54 ч. UTC

Топ новини

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- Update

23.05.2025 г., 18:53 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

McDonald's Bids Goodbye to CosMc's, Its Space Alien-Themed Spinoff -- WSJ

23.05.2025 г., 18:52 ч. UTC

Придобивния, сливания и поглъщания

DDC Enterprise Issues 254,333 Class A Ordinary Shrs in Exchange for 21 BTC, Valued at About $2.28M in Current Market Price

23.05.2025 г., 18:13 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

23.05.2025 г., 18:13 ч. UTC

Пазарно говорене

Gold Trades Higher on Reminder of Risk -- Market Talk

23.05.2025 г., 18:00 ч. UTC

Топ новини

Apple's Stock Still Not Pricing in Trump's Demands - Heard on the Street -- WSJ

23.05.2025 г., 17:51 ч. UTC

Пазарно говорене
Печалби

Workday Sees Higher Bar for Guidance -- Market Talk

23.05.2025 г., 17:42 ч. UTC

Топ новини

Dow Drops, Trump Threatens EU With 50% Tariffs, Takes Aim at Apple -- WSJ

Сравнение с други в отрасъла

Ценова промяна

REVOLUTION Medicines Inc Прогноза

Ценова цел

By TipRanks

76.24% нагоре

12-месечна прогноза

Среден 70.09 USD  76.24%

Висок 80 USD

Нисък 57 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за REVOLUTION Medicines Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

12

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

40.67 / 41.96Подкрепа & съпротива

Краткосрочен план

Strong Bullish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

153 / 381 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.